BackSynAct Pharma AB Overview

SynAct Pharma AB Total Current Liabilities

Track SynAct Pharma AB's total current liabilities ($13M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$12.88M
↓ 58.66% YoYΔ $-18.27M vs prior year quarter

Peer trimmed avg / median

Loading

SynAct Pharma AB Total Current Liabilities History

Loading

SynAct Pharma AB vs. peers: Total Current Liabilities Comparison

Loading

SynAct Pharma AB Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

SynAct Pharma AB (SYNACT.ST) FAQ

SynAct Pharma AB posts a total current liabilities of $13M as of September 2026. That compares with $31M in the prior-year period — down 58.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, SynAct Pharma AB's total current liabilities was $31M. The latest reading is $13M — a 58.7% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of SynAct Pharma AB's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SYNACT.ST's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; SynAct Pharma AB's other metric pages and overview cover the third.

Judging SynAct Pharma AB against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total current liabilities easier to interpret. Start with $13M here, then scan peer and history charts to see if the gap is persistent.